ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$1.29 USD
+0.03 (2.38%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.35 +0.06 (4.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.29 USD
+0.03 (2.38%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.35 +0.06 (4.65%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 0% and 3.93%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for February 7th
by Zacks Equity Research
AMSC, META, CLX, IPA and KMPR have been added to the Zacks Rank #1 (Strong Buy) List on February 7, 2023.
New Strong Buy Stocks for February 5th
by Zacks Equity Research
EZPW, MOD, IPA, WDC and OSK have been added to the Zacks Rank #1 (Strong Buy) List on February 5, 2023.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for October 23rd
by Zacks Equity Research
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
ImmunoPrecise Antibodies Ltd. (IPA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of 35.29% and 7.09%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 1.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.33% and 1.22%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?